Actelion

This program provides selexipag (Uptravi) to patients with Buerger's disease who have a non-healing wound. The goal is to help heal the wound and control the disease. Only a single patient is enrolled in this expanded access program.

This study tests whether a higher dose (75 mg) of the drug macitentan works better than the usual dose (10 mg) at preventing serious events like hospitalization or death in people with pulmonary arterial hypertension (PAH). About 935 adults with PAH will take either the higher or…

This study tests whether adding selexipag to standard treatment can delay disease worsening in children aged 2 to 18 with pulmonary arterial hypertension (PAH), a serious lung condition. About 138 children will receive either selexipag or a placebo, and researchers will track how…

This study looks at the safety and right dose of selexipag for children aged 2 to 17 with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard for the heart to pump blood. About 63 children will take the drug to see if it works like it does in adults…